trending Market Intelligence /marketintelligence/en/news-insights/trending/rxy6br4zik5i9tth9dyfoa2 content esgSubNav
In This List

Scythian nears CannCure deal closing with equity transfer in Fla.-based clinic

Blog

Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns

Blog

Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders

Blog

Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up

Blog

Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps


Scythian nears CannCure deal closing with equity transfer in Fla.-based clinic

Scythian Biosciences Corp. said its acquisition target CannCure Investments Inc. received clearance from Florida's Department of Health to buy a 60% stake in 3 Boys Farms LLC.

Toronto-based Scythian has agreed to acquire a 70% stake in CannCure, with an option to buy the remaining 30% equity within 15 months after the deal closes.

The deal closing was subject to CannCure's acquisition of two Florida-based organizations, including 3 Boys Farms, a licensed medical marijuana treatment center.

Florida's Department of Health's office of medical marijuana also approved the transfer of 3 Boys' license to operate as a medical marijuana treatment center in the state.

The transfer of the remaining 40% stake to CannCure will close shortly after getting all required governmental approvals from the Department of Health.

Scythian Biosciences, a Canadian medical cannabis company, has previously stated that it expects to close CannCure deal on or around Oct. 15.